FORM 8
(OPD)
PUBLIC OPENING POSITION
DISCLOSURE BY A PARTY TO AN OFFER
Rules 8.1 and 8.2 of the
Takeover Code (the "Code")
1. KEY
INFORMATION
|
(a) Full name of
discloser:
|
Alliance
Pharma plc
|
|
(b) Owner or controller of
interests and short positions disclosed, if different from
1(a):
The
naming of nominee or vehicle companies is insufficient. For a
trust, the trustee(s), settlor and beneficiaries must be
named.
|
N/A
|
|
(c) Name of offeror/offeree
in relation to whose relevant securities this form
relates:
Use
a separate form for each offeror/offeree
|
Alliance
Pharma plc
|
|
(d) Is the discloser the
offeror or the offeree?
|
Offeree
|
|
(e) Date position
held:
The latest practicable date
prior to the disclosure
|
16 January
2025
|
|
(f) In addition to the
company in 1(c) above, is the discloser making disclosures in
respect of any other party to the offer?
If it is a cash offer or
possible cash offer, state "N/A"
|
N/A
|
2. POSITIONS
OF THE PARTY TO THE OFFER MAKING THE DISCLOSURE
If
there are positions or rights to subscribe to disclose in more than
one class of relevant securities of the offeror or offeree named in
1(c), copy table 2(a) or (b) (as appropriate) for each additional
class of relevant security.
(a) Interests and
short positions in the relevant securities of the offeror or
offeree to which the disclosure relates
|
Class of relevant
security:
|
Ordinary shares of 1 pence
each
|
|
|
Interests
|
Short
positions
|
|
Number
|
%
|
Number
|
%
|
|
(1) Relevant securities owned
and/or controlled:
|
Nil
|
-
|
Nil
|
-
|
|
(2) Cash-settled
derivatives:
|
Nil
|
-
|
Nil
|
-
|
|
(3) Stock-settled derivatives
(including options) and agreements to
purchase/sell:
|
Nil
|
-
|
Nil
|
-
|
|
TOTAL:
|
Nil
|
-
|
Nil
|
-
|
All
interests and all short positions should be
disclosed.
Details of any open stock-settled derivative positions
(including traded options), or agreements to purchase or sell
relevant securities, should be given on a Supplemental Form 8
(Open Positions).
Details of any securities borrowing and lending positions or
financial collateral arrangements should be disclosed on a
Supplemental Form 8 (SBL).
(b) Rights to
subscribe for new securities
|
Class of relevant security in
relation to which subscription right exists:
|
N/A
|
|
Details, including nature of
the rights concerned and relevant percentages:
|
N/A
|
3. POSITIONS
OF PERSONS ACTING IN CONCERT WITH THE PARTY TO THE OFFER MAKING THE
DISCLOSURE
|
Details of any interests,
short positions and rights to subscribe (including directors' and
other employee options) of any person acting in concert with the
party to the offer making the disclosure:
|
|
Interests of
directors
Alliance
Pharma plc ordinary shares held by directors of Alliance Pharma
plc:
|
Director
|
Number of Alliance Pharma plc
ordinary shares held
|
Percentage of total issued
share capital
|
|
Andrew
Franklin
|
192,911
|
0.03%
|
|
Richard
Jones
|
68,000
|
0.01%
|
Interests
held as options or awards by directors of Alliance Pharma plc in
ordinary shares of Alliance Pharma plc:
|
Director
|
Share Plan
|
Grant date
|
No. of Alliance Pharma plc
ordinary shares in respect of which options granted/subject to
award
|
Expiry date
|
Vesting
date
|
Exercise price per share
(£)
|
|
Andrew
Franklin
|
LTIP
Award
|
29
September 2022
|
188,505
|
29
September 2026
|
29
September 2025 (subject to performance conditions)
|
Nil
|
|
LTIP
Award
|
4 October
2023
|
568,866
|
4 October
2027
|
4 October
2026 (subject to performance conditions)
|
Nil
|
|
Unapproved Share Options
|
4
December 2015
|
500,000
|
4
December 2025
|
4
December 2018
|
0.4675
|
|
Unapproved
Share
Options
|
27
October 2016
|
155,000
|
27
October 2026
|
27
October 2019
|
0.4750
|
|
Unapproved
Share
Options
|
27
October 2016
|
400,000
|
27
October 2026
|
27
October 2021
|
0.4750
|
|
CSOP
Unapproved Options
|
15
September 2017
|
170,000
|
15
September 2027
|
15
September 2020
|
0.53
|
|
CSOP
Unapproved Options
|
5 October
2018
|
178,000
|
5 October
2028
|
5 October
2021
|
0.8160
|
|
CSOP
Approved Options
|
5
December 2019
|
19,506
|
5
December 2029
|
5
December 2022
|
0.7690
|
|
CSOP
Unapproved Options
|
5
December 2019
|
27,995
|
5
December 2029
|
5
December 2022
|
0.7690
|
|
CSOP
Unapproved Options
|
29
September 2022
|
121,900
|
29
September 2032
|
29
September 2025
|
0.5820
|
|
Nick
Sedgwick
|
LTIP
Award
|
24 June
2024
|
906,862
|
N/A
|
24 June
2027
|
Nil
|
|
Details of any open stock-settled derivative positions
(including traded options), or agreements to purchase or sell
relevant securities, should be given on a Supplemental Form 8 (Open
Positions).
Details of any securities borrowing and lending positions or
financial collateral arrangements should be disclosed on a
Supplemental Form 8 (SBL).
4. OTHER
INFORMATION
(a) Indemnity and
other dealing arrangements
|
Details of any indemnity or
option arrangement, or any agreement or understanding, formal or
informal, relating to relevant securities which may be an
inducement to deal or refrain from dealing entered into by the
party to the offer making the disclosure or any person acting in
concert with it:
Irrevocable commitments and
letters of intent should not be included. If there are no such
agreements, arrangements or understandings, state
"none"
|
|
None
|
(b) Agreements,
arrangements or understandings relating to options or
derivatives
|
Details of any agreement,
arrangement or understanding, formal or informal, between the party
to the offer making the disclosure, or any person acting in concert
with it, and any other person relating to:
(i) the voting rights
of any relevant securities under any option; or
(ii) the voting rights or
future acquisition or disposal of any relevant securities to which
any derivative is referenced:
If there are no such
agreements, arrangements or understandings, state
"none"
|
|
None
|
(c)
Attachments
Are
any Supplemental Forms attached?
|
Supplemental Form 8 (Open
Positions)
|
No
|
|
Supplemental Form 8
(SBL)
|
No
|
Date of disclosure:
|
17
January 2025
|
Contact name:
|
Chris
Chrysanthou, Group Company Secretary
|
Telephone number:
|
+44 (0)1249
591078
|
Public disclosures under Rule 8 of the Code must be made to a
Regulatory Information Service.
The
Panel's Market Surveillance Unit is available for consultation in
relation to the Code's disclosure requirements on +44 (0)20 7638
0129.
The
Code can be viewed on the Panel's website at
www.thetakeoverpanel.org.uk.
